相关实验视频

Updated: May 9, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

固定的持续时间易布鲁替尼-Venetoclax,重新定义了CLL治疗格局

Stefano Molica¹, David Allsup^1,2

¹Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK.

Hematological oncology

|April 29, 2025

概括

易布鲁替尼和维尼托克拉克斯 (IV) 的组合为慢性淋巴细胞白血病 (CLL) 提供了有效的治疗方法,实现了深度缓解. 需要进一步的研究来优化静脉输入的持续时间,并了解可测量的残留疾病 (MRD) 的意义.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

伊布鲁替尼和维尼托克拉克斯 (IV) 的固定持续时间组合代表了慢性淋巴细胞白血病 (CLL) 治疗的重大进展.
临床前数据支持ibrutinib和venetoclax的协同抗白血病作用,为它们的联合临床使用提供了强有力的理由.

研究的目的:

评估慢性淋巴细胞白血病 (CLL) 固定的持续时间的易布鲁替尼和维尼托克拉克斯 (IV) 联合治疗的疗效和结果.
确定关于最佳静脉注射持续时间和CLL患者不可检测可测残留疾病 (uMRD) 的预后意义的剩余未回答的问题.

主要方法:

对临床试验数据的综述,评估在CLL患者中ibrutinib和venetoclax的固定持续时间组合.
分析无进展生存率 (PFS) 和无法检测的可测量的残留疾病 (uMRD) 成就率.

主要成果:

静脉注射疗法在治疗前和复发/耐药的CLL中显示出PFS的显著改善.
很大一部分患者实现了不可检测的可测量的残留疾病 (uMRD),表明了深度缓解.

结论:

固定的持续时间的易布鲁替尼和维尼托克拉克斯 (IV) 组合是一种高度有效的CLL策略,导致深度缓解.
需要进一步研究以确定静脉治疗的最佳持续时间和UMRD的长期预后值,特别是在高风险的CLL子集中.

关键词:

在 CLL CLL 中.在MRD中,我们可以使用MRD.临床结果临床结果固定时间的治疗.伊布鲁替尼加维尼托克拉克斯

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...